| abstract |
The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, at least two of which are cell receptors for C5a, C5b, C5a (eg, C5aR1 Or C5L2), C5b-9 complex, and terminal complement components or intermediates such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein can be, for example, terminal complement (eg, C5b-9 complex assembly and / or activity) and / or C5a anaphylatoxin mediated inflammation (eg, inflammatory immune cells). Of C5a-mediated chemotaxis). Thus, bispecific antibodies can be used in methods of treating various complement pathway related disorders. |